Background: Most prostate cancer patients develop castration-resistant prostate cancer (CRPC) after androgen deprivation therapy treatment. CRPC growth is mediated by androgen receptor signalling driven by primary androgens synthesized largely by the CYP17A1 enzyme.
Introduction
The androgen receptor (AR) signalling pathway plays a major role in prostate cancer (PCa), and androgen deprivation therapy (ADT) by surgical or chemical castration is the standard treatment for patients with advanced PCa. After initial treatment response most of the patients, however, develop castration-resistant prostate cancer (CRPC) with a poor prognosis [1, 2] . In recent years, several clinical trials have shown that the castration-resistant growth is driven, to a large extent, by continued AR signalling, and that CRPC remains sensitive to androgens because of the sensitization and amplification of AR signalling [3] [4] [5] [6] [7] [8] . Thus, hormonal manipulation with AR blockers, in addition to steroid biosynthesis inhibitors reducing the activation of the ARmediated pathway [9] , remain the core of CRPC treatment.
Although castration leads to very low levels of circulating testosterone, androgens are still present in prostate cancer tissues at clinically relevant concentrations that activate AR signalling and promote tumour growth [10] . The synthesis of the primary androgens testosterone and dihydrotestosterone (DHT) requires a cascade of oxidative enzymes, with one of the key enzymes being CYP17A1. Consequently, CYP17A1 inhibitors have been designed for the treatment of androgen-dependent PCa. The only CYP17A1-inhibitor currently approved for the treatment of CRPC, abiraterone, has been shown to exhibit a significant overall survival benefit in a post-chemotherapy phase III study, but some abiraterone-resistant tumours still continue to present persistent AR activation [11, 12] . Therefore, there is a clear rationale for developing 5 treatments that target CYP17A1 and AR together, as this may provide a more effective response than targeting either one alone.
Here, we present ODM-204, a novel, orally administered investigational non-steroidal dual inhibitor of CYP17A1 and AR that was shown to inhibit tumour growth in the murine VCaP CRPC xenograft model [13] . In this phase I dose escalation study, the safety profile of ODM-204 was shown to be satisfactory, but its pharmacokinetic profile would bring significant challenges on the development path.
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Patients and Methods
Inclusion criteria
Eligible patients were males over the age of 18 with metastatic progressive CRPC with ongoing androgen deprivation (ADT) therapy by gonadotropin-releasing hormone (GnRH) agonist or antagonist, or bilateral orchiectomy, and serum testosterone level < 50 ng/dl at screening, as well as metastatic disease documented by bone scan, computed tomography or magnetic resonance imaging, and an Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Disease progression was defined as rising PSA (progression defined by a minimum of two rising PSA levels with an interval of at least one week apart with the screening value ≥ 2 ng/ml), soft tissue disease progression as defined by RECIST 1.1 criteria, or 2 or more new bone lesions. Brain lesions were exclusionary. The patients had provided written informed consent and the study protocol was approved by independent ethics committees at each participating centre. The study was registered on ClinicalTrials.gov (NCT02344017).
Study design and treatment
This was an open, uncontrolled, non-randomised, multicentre, tolerability and pharmacokinetic first-in-man phase I dose escalation study of ODM-204 in patients with progressive metastatic CRPC. Escalating dose levels of ODM-204 (50, 100, 200, 300 and 500 mg twice daily) were administered in sequential cohorts of 3-6 subjects together with Prednison®. ODM-204 was taken orally twice a day with food (in the morning and evening) and 5 mg of Prednison® was 7 taken once or twice a day depending on the daily dose prior to study entry. The subjects who did not experience any dose-limiting toxicity (DLT) within 24 hours after the first dose continued ODM-204 treatment with b.i.d. dosing. DLTs were defined as any of the following toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) determined to be related to ODM-204 and occurring during the first 28 days of the study treatment: grade ≥ 3 toxicity, excluding haematological toxicities, nausea, vomiting and diarrhoea; grade ≥ 3 nausea, vomiting and diarrhoea uncontrolled with antiemetic and/or anti-diarrheal therapy; grade ≥ 3 haematological toxicity lasting for ≥ 7 days; grade ≥ 4 thrombocytopenia and neutropenia; other laboratory values of ≥ grade 3 which were judged clinically significant by the investigator, or any other toxicity which in the judgement of the investigator was viewed as a DLT. Once the safety of an administered dose was established, the next dose level was administered, and the patients with previous dose level were allowed to continue treatment with ODM-204 until progression or intolerable AEs. The next dose level was started after a minimum of 3 patients had completed 28 days of treatment and after safety review by the safety monitoring board (SMB).
Pharmacokinetic assessments
On day 1, blood samples were taken predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24 h postdose after single dosing. On day 8 after repeated dosing, blood samples were taken predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 h. The plasma concentrations of ODM-204 were determined from the blood samples using liquid chromatography with tandem mass 8 spectrometry. AUC from time zero to 12 h, 24 h and infinity, maximum concentration (C max ), time to reach maximum concentration (t max ) and elimination half-life (t ½ ) were calculated using Phoenix WinNonlin software (Certara, Princeton, NJ, USA).
Antitumor activity
Serum total PSA concentration was determined every 4 weeks until 24 weeks and every 12 weeks thereafter. In case of PSA progression, a confirmatory test was obtained 3-4 weeks later.
PSA response and progression were evaluated using PCWG2 criteria for PSA progression.
Testosterone concentrations were measured from blood samples on days 1, 8 and 29 after start of treatment, as well as on week 12, week 24 and every 12 weeks thereafter.
Chest, abdomen and pelvic CT or MRI (as per investigator's discretion) was performed at screening, week 12 and every 12 weeks thereafter to evaluate soft tissue disease progression as defined by RECIST 1.1 criteria.
Statistical considerations
Adverse events (AEs) reported after administration of the study treatment were classified by System organ classes (SOC) and preferred terms using the MedDRA dictionary. The number and proportion (%) of subjects experiencing each AE was tabulated. The AEs were graded by severity and causality. PK parameters were analysed after logarithm transformation and 95% confidence interval for the geometric mean will be calculated. Descriptive statistics for 9 continuous variables were: number of observations (N), mean (MEAN), standard deviation (SD), minimum (MIN), median, maximum (MAX). In PK variables also geometric mean (GMEAN) and coefficient of variation (CV) was calculated. Because log-normal distribution, the formula CV=100*square root(exp(variance of log-transformed data)-1) was used.
Results
Patient characteristics and study drug exposure
In total, 23 patients with CRPC were enrolled into the study between 17 February, 2015 and 22 June, 2016, at four centres; three into the 50 mg twice daily dose level group, three into the 100 mg twice daily dose level group, six into the 200 mg twice daily dose level group, seven into the 300 mg twice daily dose level group, and four into the 500 mg twice daily dose level group. The cut-off date for the data included in this report was 21 December, 2017. Baseline demographics and disease characteristics are shown in Table 1 . Median time on treatment was 12.1 weeks (0.3-71.7 weeks). Nine (39%) patients continued treatment for more than 12 weeks, and 4 (17%) patients were still receiving treatment at the time of data cut-off. Adverse events Adverse events (AEs) were reported in all of the patients, and in 14 of the 23 patients (61%) these AEs were considered to be related to the study treatment. 22 (95%) of the patients suffered mild grade 1 AEs, 13 (57%) suffered moderate grade 2 AEs, and 7 (30%) suffered severe or life threatening grade 3-4 AEs. Of the serious AEs 3 (13%) were considered related to study treatment. The most common treatment related AEs were fatigue (22%), increased appetite (17%), nausea (17%), asthenia (9%), diarrhoea (9%), decreased appetite (9%), and weight decrease (9%). In 10 of the patients (43%) disease progression related AEs led to discontinuation from the study, while 6 (26%) patients were discontinued due to disease progression, 2 (9%) due to DLTs (drug hypersensitivity in one patient in the 300 mg cohort, and vomiting and nausea in one patient in the 200 mg cohort), and 4 (17%) due to reasons classified as 'other'. One patient in the 300 mg cohort died during the study period due to disease progression. In general, the occurrence of AEs was not deemed to be dose-dependent, as treatment related AEs, serious AEs, and discontinuations due to AEs were present in all the study groups in similar proportions. The most commonly reported AEs are shown in Table 2 . Pharmacokinetics (Figure 2 ). However, the testosterone decrease was not dose-dependent and all cohorts (except the 50 mg cohort) included patients who did not present testosterone decrease. The majority of the maximum testosterone decreases, including all of the decreases over 50%, were seen at day 8, after which the testosterone levels started to increase back to the baseline in most patients. PSA changes 12 PSA decreases were seen in 7 (30%) patients at week 4, and the median decrease was 47% (2-99%). At week 12, 3 (13%) patients had PSA response with a 50% or higher reduction from baseline (Figure 3 ). Out of the seven patients that showed a PSA decrease at week 4, six continued ODM-204 treatment for at least 24 weeks without discontinuation due to an AE or disease progression, and three continued in the study for more than a year (Figure 4 ).
Interestingly, one patient continued ODM-204 treatment for over 36 weeks without any initial PSA decrease, and three of the patients (patient ID: 2, 4, and 6; Figure 4 ) that had demonstrated initial PSA decrease were not discontinued from the study until several weeks after the point at which the PSA decrease had ended. The median time of ODM-204 treatment across cohorts was 12.14 weeks.
Imaging results of prostate lesions at week 12 showed that ODM-204 treatment resulted in a stable disease in one patient in the 50 and 200 mg twice daily group, and in two patients in the 500 mg twice daily group. Additionally, ODM-204 treatment also resulted in a stable disease regarding bone lesions in one patient in all of the studied dose cohorts, except in the 200 mg twice daily cohort where four patients were reported to have a stable disease bone response. 13 
Discussion
In this first-in-man dose escalation trial ODM-204 was demonstrated to be generally well tolerated in CRPC patients, with doses up to 500 mg twice daily. One DLT occurred at the 300 mg twice daily cohort but a maximum tolerated dose was not reached. The dose escalation was discontinued at the 500 mg twice daily dose level because of decreased ODM-204 plasma concentrations at the higher dose levels after repeated dosing on day 8 compared to single dosing on day 1. The most common treatment-related AEs, fatigue, increased/decreased appetite, nausea, asthenia, diarrhoea, and weight decrease, were generally of grade 1 and 2 in severity and without significant clinical consequence. The AE profile did not differ between dose levels.
These AEs are in line with previous observations showing that AR inhibitors such as enzalutamide are associated with fatigue and gastrointestinal events [14, 15] . Interestingly, ODM-204 treatment did not demonstrate cardiac adverse events, which have been associated with the CYP17A1 inhibitor abiraterone [14] . Additionally, the incidence and severity did not appear to be directly dose-related nor related to differences in the ODM-204 plasma concentration.
The interpretation of antitumor activity can be difficult in the setting of a phase I trial given that cohorts are small and doses variable, but the current study did provide some indication of the efficacy of ODM-204. Firstly, ODM-204 treatment resulted in a decrease of serum testosterone levels in most of the patients in all of the studied dose cohorts. As serum testosterone level monitoring is commonly used to verify response to ADT [16] , this confirms the androgen deprivation effect of ODM-204. Secondly, serum PSA levels were also decreased by ODM-204 treatment in 30% of the patients with 13% showing a decrease of over 50% compared to the baseline. Thirdly, the imaging results showed that ODM-204 treatment resulted in a stable disease in four patients at week 12 as well as the arrest of bone lesion progressing in at least one patient in each dose cohort. Importantly, the patients demonstrating over 50% decrease in PSA continued ODM-204 treatment for over a year without discontinuation due to an AE or disease progression, which is an encouraging outcome. Taken together, these data suggest that dual inhibition of CYP17A1 and AR could be a valuable mechanism for treatment of prostate cancer Tables and figures   Table 1 . Patient characteristics at baseline.
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